- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05198596
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above
A Phase III, Parallel Group, Prospective, Randomized, Double-blind, Active-controlled, Two-arm, Multi-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of MVC-COV1901 Compared to AZD1222 in Adult of 18 Years and Above
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ubon Ratchathani, Thailand, 34000
- Sunpasitthiprasong Hospital
-
-
Ubon Ratchathani
-
Warin Chamrap, Ubon Ratchathani, Thailand, 34190
- College of Medicine and Public Health, Ubon Ratchathani University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participant aged 18 years and above at randomization.
- Healthy adult or adult with pre-existing medical conditions who is in a stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease 3 months before enrollment and expected to remain stable for the duration of the study.
Female participant:
- A female participant is eligible if the participant is a woman of non-childbearing potential, i.e., surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal.
- If the participant is a woman of childbearing potential, she must agree to practice sexual abstinence or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Highly effective methods of contraception include:
i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine hormonal-releasing system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository iii. Azoospermic partner (vasectomized or due to medical cause), provided the partner is the sole sexual partner of the female participant and the absence of sperm has been confirmed (from medical records/examination/history).
c.Have a negative pregnancy test
- Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
- Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or breastfeeding or have plan to become pregnant within 30 days after the last administration of the study intervention.
- Employees at the investigator's site, of the Sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study.
- Currently receiving or received any investigational intervention within 30 days prior to the first dose of the study intervention.
- Administered any licensed live-attenuated vaccines within 28 days or other licensed non- live-attenuated vaccines within 7 days prior to the first dose of the study intervention.
- Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of the study intervention.
- Currently receiving or anticipate receiving concomitant immunosuppressive or immune- modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of the study intervention.
- Currently receiving or anticipate receiving treatment with tumor necrosis factor (TNF)-α inhibitors, e.g., infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of the study intervention.
- Major surgery or any radiation therapy within 12 weeks prior to the first dose of the study intervention.
- Has received any other investigational or approved COVID-19 vaccine.
- Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
- A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
- Bleeding disorder considered a contraindication to intramuscular (IM) injection or phlebotomy.
- Documented SARS-CoV-2 infection prior to the first dose of study intervention, or an individual with positive anti-SARS-CoV-2 antibody test at screening (including rapid tests).
- A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (TTS), antiphospholipid syndrome, or capillary leak syndrome.
- Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
- A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901 or AZD1222.
- Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MVC-COV1901
S-2P protein with CpG and Aluminum Hydroxide/0.5mL
|
Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
|
Active Comparator: AZD1222
ChAdOx1 nCoV-19 vaccine
|
Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of neutralizing antibody (GMT)
Time Frame: Day 1 to Day 43
|
To demonstrate the immunogenic superiority of MVC-COV1901 to AZD1222 in terms of neutralizing antibody titers at 14 days after the second vaccination -GMT ratio |
Day 1 to Day 43
|
Incidence of Adverse Event within 28 days post the second study intervention
Time Frame: Day 1 to Day 57
|
To evaluate the safety and tolerability of MVC-COV1901 compared to AZD1222 from Day 1 to 28 days after the second vaccination The number and percentage of participants with the occurrence of:
|
Day 1 to Day 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of neutralizing antibody (GMT)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • GMT |
Day 29 to Day 209
|
Immunogenicity of neutralizing antibody(SCR)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • SCR |
Day 29 to Day 209
|
Immunogenicity of neutralizing antibody(GMT ratio)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of neutralizing antibody titers from Day 29 to Day 209 • GMT ratio |
Day 29 to Day 209
|
Incidence of Adverse Event throughout study conduct
Time Frame: Day 1 to Day 209
|
To evaluate the safety of MVC COV1901 compared to AZD1222 over the study period The number and percentage of participants with the occurrence of:
|
Day 1 to Day 209
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of confirmed COVID-19 cases
Time Frame: Day 15 to Day 209
|
To estimate the efficacy of MVC-COV1901, as compared to AZD1222, in the prevention of COVID-19 in terms of :
|
Day 15 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(GMT)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • GMT |
Day 29 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(GMT ratio)
Time Frame: Day 29 to Day 209
|
To evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • GMT ratio |
Day 29 to Day 209
|
Immunogenicity of antigen-specific immunoglobulin titers(SCR)
Time Frame: Day 29 to Day 209
|
o evaluate the immunogenicity of MVC-COV1901 compared to AZD1222 in terms of antigen-specific immunoglobulin titers from Day 29 to Day 209 • SCR |
Day 29 to Day 209
|
Cell Mediated Immunity
Time Frame: Day 1 to Day 43
|
To assess cell-mediated immune response of MVC-COV1901compared to AZD1222
|
Day 1 to Day 43
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Allen Lien, MD. Dr.PH, Medigen Vaccine Biologics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-COV-32
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19 Vaccine
-
Stanford UniversityViamoCompletedCOVID-19 Vaccine Knowledge | COVID-19 Vaccine BeliefsUnited States
-
EyeGene Inc.Novotech (Australia) Pty LimitedActive, not recruiting
-
University of OxfordCompletedCOVID-19 | Vaccine ReactionUnited Kingdom
-
University of WashingtonCenters for Disease Control and PreventionRecruitingCOVID-19 | Vaccine HesitancyUnited States
-
Michigan State UniversityRecruitingCOVID-19 | Vaccine-Preventable Diseases | HPVUnited States
-
Beijing 302 HospitalRecruitingCOVID-19 | Vaccine Reaction | Patients With CancerChina
-
Pachankis, Yang I., M.D.First Affiliated Hospital of Chongqing Medical UniversityCompleted
-
University of BariLebanese UniversityCompletedVaccine Adverse Reaction | Gender | COVID-19 Vaccine Adverse ReactionItaly
-
Chulalongkorn UniversityNational Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... and other collaboratorsCompleted
-
Cancer Institute and Hospital, Chinese Academy...RecruitingCOVID-19 Vaccine | COVID-19 InfectionChina
Clinical Trials on MVC-COV1901
-
Medigen Vaccine Biologics Corp.Completed
-
Taoyuan General HospitalMedigen Vaccine Biologics Corp.Recruiting
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.Coalition for Epidemic Preparedness InnovationsCompleted
-
Medigen Vaccine Biologics Corp.CompletedCOVID-19 VaccineParaguay
-
Medigen Vaccine Biologics Corp.Completed
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Active, not recruitingCOVID-19 | Breakthrough InfectionTaiwan
-
Medigen Vaccine Biologics Corp.Completed
-
Medigen Vaccine Biologics Corp.CompletedCovid19 VaccineTaiwan, Vietnam